Protocol Single compound
Ipamorelin
Selective ghrelin-receptor agonist (GHRP) researched for GH release with minimal cortisol/prolactin effect.
Compare side by side →Compared with:CJC-1295 DAC vs Ipamorelin
Protocol card · research reference
- Starting dose
- 0.1 mg
- Studied range
- 0.1–0.3 mg
- Frequency
- 1–3× daily
- Route
- Subcutaneous
- Cycle
- 8–12 weeks
Reconstitution reference
Storage: Powder: 2–8 °C, or −20 °C for longer storage. After mixing with BAC water: 2–8 °C, use within about 4 weeks.
Ipamorelin
1–3× daily · units to draw on a U-100 syringe for a 0.1 mg dose.
| Vial | BAC water | mg/mL | Draw | Doses |
|---|---|---|---|---|
| 5 mg | 1 mL | 5 | 2 u | 50 |
| 5 mg | 2 mL | 2.5 | 4 u | 50 |
| 5 mg | 3 mL | 1.67 | 6 u | 50 |
| 10 mg | 1 mL | 10 | 1 u | 100 |
| 10 mg | 2 mL | 5 | 2 u | 100 |
| 10 mg | 3 mL | 3.33 | 3 u | 100 |
Calculate your vial
Draw to
—units
= — mL on a U-100 syringe
- Concentration
- —
- Per unit
- —
- Doses / vial
- —
Research dossier · published literature summary
01
Mechanism of action
Ipamorelin is a synthetic pentapeptide that releases growth hormone through the ghrelin (GH secretagogue) receptor, like GHRP-6. It was developed from a GHRP-1 series with the central Ala-Trp dipeptide removed.
02
Observed research endpoints
- In rat pituitary cells and in anaesthetised rats and conscious swine, GH-release potency and efficacy were similar to GHRP-6.
- In swine it did not change FSH, LH, prolactin or TSH, and unlike GHRP-6 and GHRP-2 it did not raise ACTH or cortisol across a wide dose range.
- In adult female rats, 15 days of treatment dose-dependently increased longitudinal bone growth (42 to up to 52 µm/day) without changing total IGF-I.
03
Regulatory & safety context
- Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
- Listed as prohibited in sport by the World Anti-Doping Agency.
- Published evidence is preclinical; no peer-reviewed controlled human efficacy trial is cited here.
04
Citations
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561.1998-11Preclinical study (rat, swine)Read paper ↗
- Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106–113.1999-04Preclinical study (rat)Read paper ↗
Keep exploring
Related compounds
Found in these stacks & blends
Head-to-head articles
Where researchers source it
Listings are provided for reference — always verify the latest third-party COA before purchasing.
Medvinci Research
See siteFeatured supplier · third-party tested, COA published per batch
Supplier B
TBDPlaceholder — details coming soon
Supplier C
TBDPlaceholder — details coming soon